News & Updates

The implementation of family-based treatment for overweight or obesity in paediatric primary care settings has demonstrated success, with a recent study showing that the treatment led to improved weight outcomes.

In the treatment of women with polycystic ovary syndrome (PCOS), adding myoinositol to metformin provides further benefits for improving the regularity of menstrual cycle, with subsequent gains in quality of life, according to a study.

Young people with nonalcoholic fatty liver disease (NAFLD) are at increased risk of hypertension, especially women and those with more severe hepatic steatosis, as shown in a study.

Combination treatment with pioglitazone plus a sodium-glucose co-transporter 2 (SGLT2) inhibitor helps reduce the risk of developing major adverse cardiovascular events (MACE) and heart failure in individuals with type 2 diabetes mellitus (T2DM) who have no history of cardiovascular disease (CV), as reported in a study.

A retrospective observational study of nearly 28,000 patients with type 2 diabetes mellitus (T2DM) in Hong Kong finds that use of sodium-glucose cotransporter 2 (SGLT2) inhibitors is independently associated with lower rates of ICU admission and all-cause mortality across various disease categories.

A novel endoscopic electroporation procedure, when combined with semaglutide, can eliminate the need for insulin injections for individuals with type 2 diabetes (T2D), as shown in the results of the first-in-human EMINENT study.